Fortuna is a biotechnology company that utilizes forecasting and screening technology for non-invasive assessment of embryo traits. This approach enables prospective parents to make informed decisions regarding embryo selection, enhancing the chances of successful pregnancies.
Funding
Funding not disclosed
Founders
Product
Problem
Prospective parents undergoing in vitro fertilization (IVF) face uncertainty in selecting the most viable embryos for transfer, often relying on subjective morphological assessments. Traditional embryo evaluation methods lack comprehensive insight into an embryo's developmental potential, leading to lower implantation rates and increased time to achieve a successful pregnancy.
Solution
Fortuna employs a non-invasive embryo assessment platform that leverages advanced imaging and machine learning to predict embryo traits and developmental potential. By analyzing various parameters, the platform provides a comprehensive profile of each embryo, enabling clinicians and prospective parents to make more informed decisions during the embryo selection process. This technology aims to improve IVF success rates by identifying embryos with the highest likelihood of implantation and healthy development, ultimately reducing the emotional and financial burden associated with multiple IVF cycles.
Target Audience
The primary target audience includes IVF clinics, embryologists, and prospective parents seeking to improve the success rates of their IVF treatments.
Features
- Non-invasive imaging analysis of embryo morphology and developmental kinetics
- Machine-learning algorithms that predict embryo viability and implantation potential
- Comprehensive embryo profiling reports with detailed trait assessments
- Cloud-based platform for secure data storage and analysis
- Integration with existing IVF laboratory workflows